09:41:42 EDT Mon 17 May 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:MCURF from 2020-05-18 to 2021-05-17 - 66 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2021-04-29 08:45U:MCURFNews ReleaseMINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM's Market Launch, Delivering Mental Wealth
2021-04-27 07:45U:MCURFNews ReleaseMINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM
2021-04-27 07:45U:MCURFNews ReleaseMINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM
2021-04-22 08:45U:MCURFNews ReleaseMINDCURE Announces Experienced Finance Executive Michael Wolfe as CFO and appoints Larissa Chaikowsky to its Board of Directors
2021-04-22 08:45U:MCURFNews ReleaseMINDCURE Announces Experienced Finance Executive Michael Wolfe as CFO and appoints Larissa Chaikowsky to its Board of Directors
2021-04-21 08:45U:MCURFNews ReleaseMINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions
2021-04-21 08:45U:MCURFNews ReleaseMINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions
2021-04-14 03:30U:MCURFNews ReleaseMINDCURE Announces The Addition of Daniel Herrera, A Pharmaceutical Industry Executive With Specific Experience in Medical Psychoactive Segment
2021-04-14 03:30U:MCURFNews ReleaseMINDCURE Announces The Addition of Daniel Herrera, A Pharmaceutical Industry Executive With Specific Experience in Medical Psychoactive Segment
2021-04-13 03:30U:MCURFNews ReleaseMINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company's Psychedelic Digital Therapeutics Technology Platform
2021-04-13 03:30U:MCURFNews ReleaseMINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company's Psychedelic Digital Therapeutics Technology Platform
2021-04-08 03:30U:MCURFNews ReleaseMINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors
2021-04-08 03:30U:MCURFNews ReleaseMINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors
2021-04-07 07:07U:MCURFNews ReleaseEmerging Markets Report: The Mushroom Movement
2021-03-31 07:45U:MCURFNews ReleaseMINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients
2021-03-31 07:45U:MCURFNews ReleaseMINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients
2021-03-23 07:07U:MCURFNews ReleaseEmerging Markets Report: A Psychedelic Solution to a National Crisis
2021-03-19 07:45U:MCURFNews ReleaseTy Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM's AI-Driven Psychedelic Digital Therapeutic Technology
2021-03-19 07:45U:MCURFNews ReleaseTy Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM's AI-Driven Psychedelic Digital Therapeutic Technology
2021-03-15 07:45U:MCURFNews ReleaseMINDCURE Names Tarik Lebbadi as Chief Operating Officer
2021-03-15 07:45U:MCURFNews ReleaseMINDCURE Names Tarik Lebbadi as Chief Operating Officer
2021-03-09 03:30U:MCURFNews ReleaseMINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study
2021-03-09 03:30U:MCURFNews ReleaseMINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study
2021-03-04 03:30U:MCURFNews ReleaseMINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
2021-03-04 03:30U:MCURFNews ReleaseMINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
2021-03-03 03:30U:MCURFNews ReleaseMINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research
2021-03-03 03:30U:MCURFNews ReleaseMINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research
2021-03-02 03:30U:MCURFNews ReleaseMINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada's First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
2021-03-02 03:30U:MCURFNews ReleaseMINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada's First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
2021-02-22 03:30U:MCURFNews ReleaseMind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors
2021-02-22 03:30U:MCURFNews ReleaseMind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors
2021-02-18 03:30U:MCURFNews ReleaseMINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform
2021-02-18 03:30U:MCURFNews ReleaseMINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform
2021-02-17 19:48U:MCURFNews ReleaseMind Cure Comments on Recent Promotional Activity
2021-02-17 19:48U:MCURFNews ReleaseMind Cure Comments on Recent Promotional Activity
2021-02-17 03:30U:MCURFNews ReleaseMind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
2021-02-17 03:30U:MCURFNews ReleaseMind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
2021-02-16 03:30U:MCURFNews ReleaseMINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization
2021-02-16 03:30U:MCURFNews ReleaseMINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization
2021-02-11 08:30U:MCURFNews ReleaseMINDCURE Announces Listing of Warrants
2021-02-10 09:42U:MCURFNews ReleaseMind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option
2021-01-26 08:28U:MCURFNews ReleaseMINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category
2021-01-22 11:33U:MCURFNews ReleaseMind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering
2021-01-21 12:50U:MCURFNews ReleaseMINDCURE Included in First Psychedelic ETF & North American Psychedelics Index
2021-01-21 12:50U:MCURFNews ReleaseMINDCURE Included in First Psychedelic ETF & North American Psychedelics Index
2021-01-12 03:30U:MCURFNews ReleaseMind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
2021-01-12 03:30U:MCURFNews ReleaseMind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
2021-01-06 03:30U:MCURFNews ReleaseMind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research
2021-01-06 03:30U:MCURFNews ReleaseMind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research
2020-12-31 03:30U:MCURFNews ReleaseMind Cure Announces Retail Roll Out of Nootropics Lineup Across North America with Body Energy Club
2020-12-31 03:30U:MCURFNews ReleaseMind Cure Announces Retail Roll Out of Nootropics Lineup Across North America with Body Energy Club
2020-12-29 03:30U:MCURFNews ReleaseMind Cure Announces Novel Supplement Product to Address Teen Wellness
2020-12-29 03:30U:MCURFNews ReleaseMind Cure Announces Novel Supplement Product to Address Teen Wellness
2020-12-10 03:30U:MCURFNews ReleaseMind Cure Moves into Psychedelic Assisted Therapy with British Columbia Location Offering Ketamine and Psilocybin Therapy
2020-12-10 03:30U:MCURFNews ReleaseMind Cure Moves into Psychedelic Assisted Therapy with British Columbia Location Offering Ketamine and Psilocybin Therapy
2020-12-09 15:08U:MCURFNews ReleaseMind Cure Health Inc. Announces Participation in the Benzinga Global Small Cap Conference
2020-12-08 03:30U:MCURFNews ReleaseMind Cure Announces its Research Program with Psychedelic Compounds
2020-12-08 03:30U:MCURFNews ReleaseMind Cure Announces its Research Program with Psychedelic Compounds
2020-12-02 03:30U:MCURFNews ReleaseMind Cure Announces Eligibility for DTC Trading
2020-12-02 03:30U:MCURFNews ReleaseMind Cure Announces Eligibility for DTC Trading
2020-12-01 08:30U:MCURFNews ReleaseMind Cure Promotes Kelsey Ramsden to President and Chief Executive Officer
2020-12-01 08:30U:MCURFNews ReleaseMind Cure Promotes Kelsey Ramsden to President and Chief Executive Officer
2020-11-19 12:45U:MCURFNews ReleaseMind Cure Announces Closing of Oversubscribed $3.6 Million Offering
2020-11-13 07:57U:MCURFNews ReleaseMind Cure Announces Non-Brokered Private Placement of $3 Million
2020-11-10 03:30U:MCURFNews ReleaseMind Cure Announces Hiring of Award-Winning Experimental Scientist Dr. Ryan Hartwell as Chief Science Officer
2020-11-10 03:30U:MCURFNews ReleaseMind Cure Announces Hiring of Award-Winning Experimental Scientist Dr. Ryan Hartwell as Chief Science Officer